

Patent Claims

Sub
A1

1. Use of selective PDE 2 inhibitors for producing pharmaceuticals for improving perception, concentration, learning and/or memory.

5

2. Use according to Claim 1 for the prophylaxis and/or treatment of disorders of perception, concentration, learning and/or memory.

10 3 4

3. Use according to Claim 2, where the disorder is a result of dementia.

4. Use according to Claim 2, where the disorder is a result of stroke or craniocerebral trauma.

5. Use according to Claim 2, where the disorder is a result of Alzheimer's disease.

15

6. Use according to Claim 2, where the disorder is a result of Parkinson's disease.


7. Use according to Claim 2, where the disorder is a result of depression.

8. Use according to Claim 2, where the disorder is a result of dementia with frontal lobe degeneration.

9. Use according to any of Claims 1 to 8, where the selective PDE 2 inhibitor is a compound of the general formula (I)

25

112



in which

5

A=D represents N=N, N=CH or CR⁵=N, in which R⁵ denotes hydrogen, methyl, ethyl or methoxy,

R¹ and R² represent, together with the adjacent carbon atom, hydroxy-methylene or carbonyl, and

10

R³ and R⁴ represent independently of one another methyl, ethyl, methoxy, ethoxy or a radical of the formula SO₂NR⁶R⁷,

in which

15

R⁶ and R⁷ denote, independently of one another, hydrogen, C₁-C₆-alkyl, C₃-C₇-cycloalkyl, or

20

R⁶ and R⁷ form, together with the adjacent nitrogen atom, an azetidin-1-yl, pyrrol-1-yl, piperid-1-yl, azepin-1-yl, 4-methylpiperazin-1-yl or morpholin-1-yl radical,

or one of its salts.